Coronavirus Update: NJ Company Receives Approval To Begin Clinical Trials For Immunotherapy Treatment

FLORHAM PARK, N.J. (CBSNewYork) -- The Food and Drug Administration has just given approval for a New Jersey company to use immunotherapy to treat adults with the coronavirus.

Celularity, based in Florham Park, will begin clinical trials on as many as 86 patients with COVID-19.

In the treatment, so-called natural killer cells from human placentas will be given to corona-infected patients.

It's believed those cells shield a fetus from the coronavirus and could also destroy the virus in sick adults.

The treatment is currently tested against certain types of cancer.

Read more
f

We and our partners use cookies to understand how you use our site, improve your experience and serve you personalized content and advertising. Read about how we use cookies in our cookie policy and how you can control them by clicking Manage Settings. By continuing to use this site, you accept these cookies.